Romaguera, Jorge E <br/><br/>
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2005 
 - 7013-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2005.01.1825  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Treatment Outcome<br/>Vincristine--administration & dosage